0
By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.
Don’t have an account? Signup
X4 Pharmaceuticals announced on Monday, April 29, 2024, that it has received FDA approval in the United States to treat a rare genetic immunodeficiency disease in patients 12 years and older using its mavorixafor.
Share this article
If you liked this article share it with your friends.they will thank you later